Related Experiment Videos
Clinical trial with CIBA 1906 in lepromatous leprosy
Leprosy in India
|April 1, 1981
Summary
CIBA 1906 showed good tolerance and mild reactions in 50 leprosy patients intolerant to dapsone. While clinical improvement was observed in 72%, its antibacterial activity was not superior to dapsone.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Leprosy management often requires alternative therapies due to dapsone intolerance.
- Dapsone is a primary treatment for leprosy, but side effects can limit its use.
Purpose of the Study:
- To evaluate the efficacy and tolerability of CIBA 1906 in lepromatous leprosy patients.
- To assess clinical improvement and bacterial index reduction with CIBA 1906.
Main Methods:
- A clinical trial involving 50 patients with lepromatous leprosy.
- Patients included were intolerant to dapsone therapy.
- Assessment of clinical response, lepra reactions, and bacterial index (BI).
Main Results:
- CIBA 1906 was well-tolerated with infrequent and mild lepra reactions.
- Clinical improvement occurred in 72% of patients; 28% showed no significant change.
- A mean BI reduction of 0.4 was observed in 62% of cases.
Conclusions:
- CIBA 1906 is a viable alternative for dapsone-intolerant leprosy patients.
- The drug demonstrated acceptable tolerability and moderate clinical efficacy.
- Antibacterial efficacy of CIBA 1906 was comparable to dapsone.